IMGN632
- Generic Name
- IMGN632
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 218
- Registration Number
- NCT04086264
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 179
- Registration Number
- NCT03386513
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath